Genprex, Inc. Common Stock

GNPXNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
2.11 USD
↘ 0.18 (7.86%)AT CLOSE (03:59 PM EDT)
2.15
↗ 0.04 (1.75%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
2.15
↗ 0.04 (1.75%)
🔴Market: CLOSED

GNPX is currently priced at $2.11. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest GNPX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 16, 2026.

Open?$2.27
High?$2.32
Low?$2.10
Prev. Close?$2.29
Volume?127.9K
Avg. Volume?220.1K
VWAP?$2.20
Rel. Volume?0.58x
Bid / Ask
Bid?$2.10 × 200
Ask?$2.24 × 500
Spread?$0.14
Midpoint?$2.17
Valuation & Ratios
Market Cap?1.9M
Shares Out?819.7K
Float?503.7K
Float %?99.8%
P/E Ratio?N/A
P/B Ratio?0.13
EPS?-$20.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingHealthcare - Oncology›Targeted Therapy & Precision Oncology
Employees
13
Market Cap
1.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.genprex.com
Listed
2018-03-29
Address
3300 BEE CAVE ROAD SUITE 650-227
AUSTIN, TX 78746
Phone: 512-537-7997
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
34
Piotroski F-Score?0/9Weak
Altman Z-Score?-16.32Distress
Confidence?44%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?19.27%High
Short Interest?97.1K
Days to Cover?1.0
Free Float503.7K
Avg Daily Volume361.7K
Settlement Date2026-09-30
Financial Health
Current Ratio?6.77Strong
Quick Ratio?6.77Strong
Cash Ratio?6.47Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.13CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-111.5%WEAK▾
ROA?
S&P
3
-96.3%WEAK▾
Cash Flow & Enterprise
FCF?$-15562705
Enterprise Value?$-13277069
Fundamentals ratios updated end of day
MarketsMoversWatchlist